SYN Synthetic Biologics Inc

Synthetic Biologics Inc is a late-stage biotechnology company focused on developing gut microbiome therapeutics. It is also developing monoclonal antibody therapies for the treatment of pertussis.

$0.48
As of 05/10/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/26/2007
Outstanding shares:  132,042,538
Average volume:  3,420,085
Market cap:   $60,713,159
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    87164U201
ISIN:        US87164U2015
Sedol:      BG4SNW4
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   86.38
PS ratio:   0.00
Return on equity:   -12.08%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy